RedHill Biopharma has signed an exclusive licensing agreement for the commercialisation of Entera Health’s gastrointestinal speciality products, Donnatal and EnteraGam.
Gastrointestinal
Under the terms of the agreement, RedHill will pay Entera Health royalties on net sales generated from the sale of EnteraGam and will have the exclusive US rights for all indications for human use. Additionally, RedHill will be granted certain US rights to Entera Health’s FDA-approved dicyclomine hydrochloride oral solution USP.
“We look forward to initiating the promotion of Donnatal and EnteraGam in mid-2017,” said Guy Goldberg, chief business officer of RedHill. “We are currently in advanced stages of building RedHill’s commercial operations in the US and are excited to complement our product portfolio with a second commercial product geared towards gastroenterologists.”